MAP855 |
| Katalog-Nr.GC64904 |
MAP855 ist ein hochpotenter, selektiver, ATP-kompetitiver und oral aktiver MEK1/2-Kinase-Inhibitor (MEK1 ERK2 Kaskade IC50=3 nM, pERK EC50=5 nM). MAP855 zeigt eine gleichstarke Hemmung von Wildtyp- und Mutanten-MEK1/2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1660107-77-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2[1].
MAP855 (compound 30) has single-digit nM inhibition of pERK and proliferation in A375 cells (pERK EC50=5 nM)[1].
MAP855 (3 mg/kg for i.v., 10 mg/kg for p.o.; single) has good oral bioavailability and medium clearance in rodents[1].MAP855 (30 mg/kg; p.o., b.i.d, 14 days) achieves comparable efficacy to trametinib dosed at the mouse MTD without any body weight loss[1].Pharmacokinetic Parameters of MAP855 in mouse, rat and dog[1]. mouse rat dog CL [mL/min*kg]323522Vss [l/kg]2.62.01.8AUC po d.n. [μM*h]0.40.61.4 Oral BAV [% F]4465100
[1]. Poddutoori R, et al. Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action. J Med Chem. 2022;65(5):4350-4366.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *